London, United Kingdom
Verdiva Bio, founded in 2025, is an emerging leader in the field of cardiometabolic health, with its headquarters in the United Kingdom. The company is committed to developing next-generation therapies aimed at transforming the lives of individuals suffering from obesity and related complications, focusing on more patient-friendly therapeutic options.
Their flagship product, VRB-101, is an oral GLP-1 peptide which has shown best-in-class efficacy potential in a phase 1 study conducted in Australia. This study also confirmed the feasibility of a once-weekly dosing regimen. Alongside VRB-101, Verdiva Bio is advancing a range of amylin molecules, including oral and subcutaneous agonists, which are designed for enhanced efficacy, improved tolerability, and healthier weight loss.
Their impressive Series A financing of $411.00M was led by prominent investors including General Atlantic, Lilly Asia Ventures, RA Capital Management, Forbion, OrbiMed, Logos Capital, and LYFE Capital, attesting to the strong market confidence in their innovative approach.
-Ltd.-logo. "CV6 Therapeutics, (NI) Ltd."){kind=logo}
